Conditions: Carcinoma, Renal Cell
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 106
Healthy volunteers: no

Brief summary:
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: SU011248
Intervention descriptions: intervention 1: 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity

Protocol document: